Serap Sankoh

9.0k total citations · 3 hit papers
67 papers, 6.6k citations indexed

About

Serap Sankoh is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Serap Sankoh has authored 67 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 34 papers in Epidemiology and 20 papers in Immunology. Recurrent topics in Serap Sankoh's work include Inflammatory Bowel Disease (35 papers), Microscopic Colitis (31 papers) and Histone Deacetylase Inhibitors Research (10 papers). Serap Sankoh is often cited by papers focused on Inflammatory Bowel Disease (35 papers), Microscopic Colitis (31 papers) and Histone Deacetylase Inhibitors Research (10 papers). Serap Sankoh collaborates with scholars based in United States, Canada and United Kingdom. Serap Sankoh's co-authors include Brian G. Feagan, Asit Parikh, Irving H. Fox, Bruce E. Sands, William J. Sandborn, Jean‐Frédéric Colombel, Catherine Milch, Paul Rutgeerts, Jing Xu and Silvio Danese and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Serap Sankoh

67 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
The safety of vedolizumab for ulcerative colitis and Crohn's disease

2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Serap Sankoh United States	20	4.8k	3.8k	2.1k	1.5k	577	67	6.6k
Walter Reinisch Austria	32	5.3k 1.1×	4.1k 1.1×	1.8k 0.9×	2.0k 1.3×	538 0.9×	71	7.2k
Milan Lukáš Czechia	33	4.3k 0.9×	3.2k 0.9×	1.9k 0.9×	1.6k 1.0×	453 0.8×	156	6.0k
Niels Vande Casteele United States	43	5.1k 1.1×	3.6k 1.0×	2.9k 1.4×	1.2k 0.8×	474 0.8×	158	6.8k
Jewel Johanns United States	32	8.6k 1.8×	6.5k 1.7×	3.4k 1.6×	2.3k 1.5×	516 0.9×	119	10.4k
Filip Baert Belgium	42	8.6k 1.8×	6.6k 1.8×	2.8k 1.3×	3.1k 2.0×	942 1.6×	137	11.0k
Byong Duk Ye South Korea	44	3.2k 0.7×	2.9k 0.8×	964 0.5×	3.0k 1.9×	535 0.9×	422	7.4k
Omoniyi J. Adedokun United States	24	4.0k 0.8×	2.8k 0.8×	1.7k 0.8×	957 0.6×	217 0.4×	70	4.7k
Sang Hyoung Park South Korea	37	2.5k 0.5×	2.0k 0.5×	639 0.3×	1.7k 1.1×	409 0.7×	252	4.5k
Mario Cottone Italy	41	3.3k 0.7×	4.5k 1.2×	699 0.3×	2.6k 1.7×	337 0.6×	163	7.5k
Robert Löfberg Sweden	49	5.7k 1.2×	4.4k 1.2×	945 0.5×	2.6k 1.7×	400 0.7×	140	8.0k

Countries citing papers authored by Serap Sankoh

Since Specialization

Citations

This map shows the geographic impact of Serap Sankoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serap Sankoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serap Sankoh more than expected).

Fields of papers citing papers by Serap Sankoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serap Sankoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serap Sankoh. The network helps show where Serap Sankoh may publish in the future.

Co-authorship network of co-authors of Serap Sankoh

This figure shows the co-authorship network connecting the top 25 collaborators of Serap Sankoh. A scholar is included among the top collaborators of Serap Sankoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serap Sankoh. Serap Sankoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations

Sullivan, Ryan J., Stergios J. Moschos, Melissa L. Johnson, et al.. (2019). Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy. Cancer Research. 79(13_Supplement). CT072–CT072. 31 indexed citations

Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2018). OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. Journal of Thoracic Oncology. 13(10). S330–S330. 17 indexed citations

Parikh, Asit, Eugene O. Major, Irving H. Fox, et al.. (2018). A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Safety. 41(8). 807–816. 4 indexed citations

Juric, Dejan, Johann S. de Bono, Patricia LoRusso, et al.. (2017). A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 23(17). 5015–5023. 76 indexed citations

Rosario, Maria, Jonathan French, Nathanael L. Dirks, et al.. (2017). Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. Journal of Crohn s and Colitis. 11(8). 921–929. 126 indexed citations

Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851. 563 indexed citations breakdown →

Dearnaley, David P., Daniel R. Saltzstein, John E. Sylvester, et al.. (2016). Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC). Annals of Oncology. 27. vi249–vi249. 7 indexed citations

Rosario, Maria, Timothy Wyant, Timothy Leach, et al.. (2016). Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Clinical Drug Investigation. 36(11). 913–923. 38 indexed citations

10.

Feagan, Brian G., David T. Rubin, Silvio Danese, et al.. (2016). Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology. 15(2). 229–239.e5. 158 indexed citations

11.

Rosario, Maria, et al.. (2015). DOP040. Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 9(suppl 1). S46–S46. 8 indexed citations

12.

Feagan, B G, William J. Sandborn, Matthew D. Smyth, et al.. (2014). P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn s and Colitis. 8. S276–S277. 8 indexed citations

13.

Wyant, Tim, Serap Sankoh, Yuemei Wang, et al.. (2014). Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 64(1). 77–83. 134 indexed citations

14.

LoRusso, Patricia, Karthik Venkatakrishnan, E. Gabriela Chiorean, et al.. (2013). Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Investigational New Drugs. 32(1). 160–170. 13 indexed citations

15.

Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 369(8). 699–710. 2048 indexed citations breakdown →

16.

Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 369(8). 711–721. 2011 indexed citations breakdown →

17.

Parikh, Asit, Timothy Leach, Tim Wyant, et al.. (2011). Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. Inflammatory Bowel Diseases. 18(8). 1470–1479. 182 indexed citations

18.

Rosenstock, Julio, Serap Sankoh, & James F. List. (2008). Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*. Diabetes Obesity and Metabolism. 10(5). 376–386. 195 indexed citations

19.

Johnson, Margaret, Beatriz Grinsztejn, Claudia Rodríguez, et al.. (2005). Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 19(7). 685–694. 203 indexed citations

20.

Garber, A. J., E. Klein, Simon Bruce, Serap Sankoh, & Pharis Mohideen. (2005). Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obesity and Metabolism. 8(2). 156–163. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact